NATURAL HISTORY STUDY OF THE DEVELOPMENT OF TYPE I DIABETES

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 这项研究的目的是发展未来的研究，这将有助于研究人员更多地了解1型糖尿病的预防和糖尿病是如何发生的。 1型糖尿病患者的亲属患这种疾病的风险比没有家族史的人高10到15倍。 因此，我们有兴趣研究1型糖尿病患者的近亲。 该研究分为三个阶段：筛选阶段1，基线风险评估阶段2和随访风险评估阶段3。 第一阶段-研究的筛选阶段包括检测血液中与糖尿病相关的自身抗体。自身抗体是由身体产生的蛋白质？的免疫系统。 如果这些蛋白质存在，这可能意味着胰腺中产生胰岛素的细胞受损。 1型糖尿病患者的血液中可以检测到自身抗体。可以看到几种不同类型的自身抗体。 第二阶段-做更多的测试，以找出或估计1型糖尿病的风险。 第三阶段-是针对那些测试结果显示他们比其他人患1型糖尿病的风险更高的受试者。它涉及几个正在进行的风险评估测试，看看这些受试者是否有资格参加任何糖尿病预防试验

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the study is to develop future studies that will help researchers to learn more about the prevention of type 1 diabetes and how diabetes occurs. Relatives of people with type 1 diabetes have a 10 to 15 times greater risk for the disease than people with no family history. Because of this, we are interested in looking at close blood relatives of people with type 1 diabetes. The study is divided into three phases: Screening Phase 1, Baseline Risk Assessment Phase 2, and Follow-Up Risk Assessments Phase 3. Phase I - The screening phase of the study includes testing for diabetes related autoantibodies in the blood. Autoantibodies are proteins that are made by the body?s immune system. If these proteins are present, it could mean that cells in the pancreas that produce insulin are damaged. Autoantibodies can be found in the blood years before type 1 diabetes occurs. Several different kinds of autoantibodies can be seen. Phase II - More testing done to find out or estimate the risk for type 1 diabetes. Phase III - Is for those subjects whose test results showed that they are at a higher risk of developing type 1 diabetes than others. It involves several ongoing risk assessment tests to see if these subjects might be eligible to participate in any diabetes prevention trials